



Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN- α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial

Bas D. Koster¹ · Saskia J. A. M. Santegoets^{1,2} · Jorien Harting¹ · Arnold Baars¹ · S. Marieke van Ham^{3,4} · Rik J. Scheper³ · Erik Hooijberg^{3,5} · Tanja D. de Gruij¹ · Alfons J. M. van den Eertwegh¹

Published online: 27 March 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Correction to: Cancer Immunology, Immunotherapy
<https://doi.org/10.1007/s00262-019-02320-0>

In the original publication of the article the following abstract and keywords were inadvertently omitted.

Abstract

Background In this study the toxicity and efficacy of an irradiated autologous tumor cell vaccine (ATV) co-injected with a class-B CpG oligodeoxynucleotide (CpG-B) and GM-CSF, followed by systemic CpG-B and IFN- α administration, were examined in patients with metastatic renal cell carcinoma (mRCC).

Methods A single-arm Phase II trial was conducted, in which patients with mRCC were intradermally injected

with a minimum of three whole-cell vaccines containing $0.7\text{--}1.3 \times 10^7$ irradiated autologous tumor cells (ATC), admixed with 1 mg CpG-B and 100 μg GM-CSF, followed by bi-weekly s.c. injections with 8 mg CpG-B and s.c. injections with 6 MU IFN- α three times per week.

Results Fifteen patients were treated according to the protocol. Treatment was well tolerated. Objective clinical responses occurred in three patients, including one long-term complete response. Disease stabilization occurred in another three patients. Positive delayed type hypersensitivity (DTH) responses to ATC were absent before treatment but present in 13 out of 15 patients during treatment. Immune monitoring revealed activation of plasmacytoid dendritic cells, non-classical monocytes and up-regulation of both PD-1 and CTLA4 on effector T cells upon treatment. Moreover, a pre-existing ex vivo IFN- γ response to ATC was associated with clinical response.

Conclusions ATV combined with systemic CpG-B and IFN- α is tolerable, safe, immunogenic and able to elicit anti-tumor responses in patients with mRCC. Immune activation and treatment-induced up-regulation of PD-1 and CTLA4 on circulating T cells further suggest an added benefit of combining this approach with immune checkpoint blockade.

Keywords Autologous tumor cell vaccination · CpG-B · IFN-alpha · GM-CSF · Metastatic renal cell cancer

The original article can be found online at <https://doi.org/10.1007/s00262-019-02320-0>.

✉ Alfons J. M. van den Eertwegh
vandeneertwegh@vumc.nl

¹ Departments of Medical Oncology, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

² Department of Medical Oncology, Leiden University Medical Center, Hippocratespad 21, 2333 ZD Leiden, The Netherlands

³ Departments of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

⁴ Department of Immunopathology, Landsteiner Laboratory, Amsterdam UMC and Swammerdam Institute for Life Sciences, Sanquin Research, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

⁵ Department of Pathology, Antoni van Leeuwenhoek/Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.